Sun Pharma shares crash as much as 11% on reports SEBI may reopen insider trading case

In a letter sent to the capital markets regulator SEBI, the whistle-blower accused that Sun Pharmaceuticals had committed corporate governance and tax-related lapses, apart from other securities market-related violations.

from The Financial ExpressThe Financial Express https://ift.tt/2PfYNlY
via IFTTT